Age 75+ No Bar to Rivaroxaban Benefit vs Warfarin: ROCKET-AFAge 75+ No Bar to Rivaroxaban Benefit vs Warfarin: ROCKET-AF

The trial's very elderly had more clinical events and bleeding issues than younger patients, but their relative benefit from the new oral anticoagulant was similar. Heartwire
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news